AT1 FY21 - General Discussion + FA, page-1861

Yes. RATs are not only a financial win for the company, they are also an indicator of a broader cultural shift - if it is OK for me to get tested for COVID at home, why wouldn’t it be OK to get tested for HIV, Flu, or Celiac disease? In general, it is a win for point-of-care testing.

Besides, we still have Febridx to come through, the work of Bondi Partners (with shares optioning in April 2022 at .40), new US recruitments, and the growing HIV business (135+ countries).

I for one am happy the shares are not at 13c. Although when it went to 36c not too long, I was hoping that I would get one more chance at the lower rate - which we did at around 16c.

Meanwhile, I am taking @Roccoroll advice and building myself a cryopreservation chamber to pass the days.